Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,206
Out of 5,127 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $40.73 | +3.12% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $170.58 | +119.84% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $83.13 | +38.34% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $80.62 | +14.12% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $14.72 | -18.48% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.55 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $72.92 | +23.42% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $260.68 | +3.58% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $114.15 | -40.43% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.26 | +267.05% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $110.01 | +149.98% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $22.50 | +64.44% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $68.43 | -12.32% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $98.38 | -64.42% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $292.89 | -72.34% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $40.73
Upside: +3.12%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $170.58
Upside: +119.84%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $83.13
Upside: +38.34%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $80.62
Upside: +14.12%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $14.72
Upside: -18.48%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.55
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $72.92
Upside: +23.42%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $260.68
Upside: +3.58%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $114.15
Upside: -40.43%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.26
Upside: +267.05%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $110.01
Upside: +149.98%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $22.50
Upside: +64.44%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $68.43
Upside: -12.32%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $98.38
Upside: -64.42%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $292.89
Upside: -72.34%